内容紹介
Summary
We encountered a case of multiple metastases from breast cancer. The patient was administered palbociclib, which was a new checkpoint inhibitor. The patient received various chemotherapies and endocrine therapies. We observed episode of care, a harm phenomenon, and tolerability. We did not recognize adverse events more severe than Grade 3 during the 6 weeks after initiating palbociclib therapy. Diagnostic imaging showed that the metastatic lesions maintained stable disease during the 6 weeks after initiating palbociclib therapy. This case suggested that palbociclib therapy is useful for patients with metastatic breast cancer.
要旨
新規checkpoint inhibitorであるpalbociclibを内分泌受容体陽性の転移・再発乳癌症例に対して投与し,治療経過・有害事象・忍容性について観察を行った。投与開始後6週間の時点で,Grade 3以上の有害事象は認めず,画像診断ではSDを保っており,腫瘍マーカーは低下傾向であった。転移・再発乳癌に対してpalbociclibの投与は忍容性も良好であり,有用である可能性が示唆された。
目次
We encountered a case of multiple metastases from breast cancer. The patient was administered palbociclib, which was a new checkpoint inhibitor. The patient received various chemotherapies and endocrine therapies. We observed episode of care, a harm phenomenon, and tolerability. We did not recognize adverse events more severe than Grade 3 during the 6 weeks after initiating palbociclib therapy. Diagnostic imaging showed that the metastatic lesions maintained stable disease during the 6 weeks after initiating palbociclib therapy. This case suggested that palbociclib therapy is useful for patients with metastatic breast cancer.
要旨
新規checkpoint inhibitorであるpalbociclibを内分泌受容体陽性の転移・再発乳癌症例に対して投与し,治療経過・有害事象・忍容性について観察を行った。投与開始後6週間の時点で,Grade 3以上の有害事象は認めず,画像診断ではSDを保っており,腫瘍マーカーは低下傾向であった。転移・再発乳癌に対してpalbociclibの投与は忍容性も良好であり,有用である可能性が示唆された。